Stunningeffekte bei der Radioiodtherapie des Schilddrüsenkarzinoms: Existenz, klinische Auswirkungen und Auswege

Bei der Radioiodtherapie maligner Schilddrusenerkran-kungen kann die im Rahmen der Vordiagnostik verab-reichte Iod-131-Aktivitat die Fahigkeit von Schilddrusen-und Schilddrusenkarzinomzellen mindern, die nachfol-gende therapeutische Iod-131-Aktivitat aufzunehmen und somit zum Therapieversagen beitragen. Dieser so genannte Stunningeffekt wird in der Literatur kontrovers diskutiert. Die vorliegende Arbeit gibt einen Uberblick unter Wertung der vorhandenen Literatur, um den aktuellen Kenntnisstand zur Existenz von Stunning, deren Auswirkungen und moglichen Gegenmasnahmen aufzuzeigen.

[1]  W. Lees,et al.  The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  S. Larson,et al.  Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.

[3]  R. Kloos,et al.  Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? , 2002, The Journal of clinical endocrinology and metabolism.

[4]  A. Pinchera,et al.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. , 2002, The Journal of clinical endocrinology and metabolism.

[5]  M. Dempsey,et al.  Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  R. Cavalieri,et al.  I-123 Diagnostic Thyroid Tumor Whole-Body Scanning with Imaging at 6, 24, and 48 Hours , 2002, Clinical nuclear medicine.

[7]  R. Foley,et al.  The role of 123I‐diagnostic imaging in the follow‐up of patients with differentiated thyroid carcinoma as compared to 131I‐scanning: avoidance of negative therapeutic uptake due to stunning , 2001, Clinical endocrinology.

[8]  L. Braverman,et al.  Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  G. Braunstein,et al.  The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. , 2001, The Journal of clinical endocrinology and metabolism.

[10]  M. Kárný,et al.  Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M. Dempsey,et al.  Thyroid stunning after (131)I diagnostic whole-body scanning. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  A. Alavi,et al.  Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer , 2001, Clinical nuclear medicine.

[13]  R. O'mara,et al.  Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Humm,et al.  Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  J. Muratet,et al.  Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. Clerc,et al.  Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma , 1998, European Journal of Nuclear Medicine.

[17]  I. Mcdougall,et al.  74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. , 1997, Nuclear medicine communications.

[18]  Xiao-Hua Zhou,et al.  Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. , 1997, Thyroid : official journal of the American Thyroid Association.

[19]  M. Žuvić,et al.  Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I. , 1996, Nuclear medicine communications.

[20]  A. Perkins,et al.  Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole‐body scans: Comparison of quantification and visual assessment of thyroid bed uptake , 1996, Nuclear medicine communications.

[21]  F. D. Thomas.  The significance of I-131 scan doses in patients with thyroid cancer: determination of ablation: concise communication. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  G. Braunstein,et al.  Thyroid stunning. , 2003, Thyroid : official journal of the American Thyroid Association.

[23]  A. Alavi,et al.  Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  S. Loncaric,et al.  As soon as possible is already to late , 2001 .

[25]  E. Baudin,et al.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.

[26]  M. Dietlein,et al.  Leitlinie zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom , 1999 .

[27]  C. Kao,et al.  Stunning Effects after a Diagnostic Dose of Iodine-131 , 1998, Nuklearmedizin.

[28]  H. Park,et al.  Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. , 1994, Thyroid : official journal of the American Thyroid Association.

[29]  A. Chilingarian,et al.  Using neutron monitor network data to improve the detection of space weather events , 2007 .